Primecap Management Co. CA Acquires 32,942 Shares of LivaNova PLC $LIVN

Primecap Management Co. CA increased its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 0.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,641,352 shares of the company’s stock after acquiring an additional 32,942 shares during the period. Primecap Management Co. CA owned approximately 8.50% of LivaNova worth $208,954,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. CWM LLC lifted its holdings in shares of LivaNova by 52.3% during the first quarter. CWM LLC now owns 871 shares of the company’s stock valued at $34,000 after purchasing an additional 299 shares during the last quarter. State of Michigan Retirement System boosted its holdings in LivaNova by 2.3% in the second quarter. State of Michigan Retirement System now owns 13,111 shares of the company’s stock worth $590,000 after acquiring an additional 300 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of LivaNova by 182.5% in the second quarter. GAMMA Investing LLC now owns 630 shares of the company’s stock worth $28,000 after acquiring an additional 407 shares during the last quarter. Central Pacific Bank Trust Division increased its holdings in shares of LivaNova by 9.5% during the second quarter. Central Pacific Bank Trust Division now owns 4,827 shares of the company’s stock valued at $217,000 after acquiring an additional 420 shares in the last quarter. Finally, Retirement Systems of Alabama raised its position in shares of LivaNova by 0.8% in the 2nd quarter. Retirement Systems of Alabama now owns 66,644 shares of the company’s stock worth $3,000,000 after purchasing an additional 554 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Price Performance

NASDAQ LIVN opened at $53.89 on Wednesday. The stock has a market capitalization of $2.94 billion, a price-to-earnings ratio of -13.85 and a beta of 1.00. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $58.91. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09. The business’s fifty day moving average price is $53.52 and its 200-day moving average price is $49.25.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $1.11 EPS for the quarter, topping the consensus estimate of $0.91 by $0.20. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The company had revenue of $357.80 million during the quarter, compared to analyst estimates of $342.32 million. During the same quarter in the previous year, the company posted $0.90 earnings per share. LivaNova’s revenue was up 12.5% compared to the same quarter last year. LivaNova has set its FY 2025 guidance at 3.800-3.90 EPS. On average, equities analysts predict that LivaNova PLC will post 2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

LIVN has been the topic of several recent analyst reports. Mizuho increased their price objective on shares of LivaNova from $65.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Robert W. Baird boosted their price objective on shares of LivaNova from $63.00 to $70.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. Wall Street Zen raised LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 9th. Barclays lifted their target price on LivaNova from $55.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, August 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 price target on shares of LivaNova in a report on Wednesday, September 3rd. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $62.43.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.